New anti inflammatory drugs 2018

Here are some new anti-inflammatory drugs that were approved or made significant progress in 2018:

  1. Ozanimod (Zeposia): Approved by the FDA in March 2018, ozanimod is an oral medication used to treat moderate to severe ulcerative colitis. It is a sphingosine 1-phosphate receptor modulator that reduces inflammation in the gut.
  2. Upadacitinib (Rinvoq): Approved by the FDA in June 2018, upadacitinib is an oral medication used to treat moderate to severe rheumatoid arthritis. It is a Janus kinase (JAK) inhibitor that reduces inflammation and joint damage.
  3. Tofacitinib (Xeljanz): Approved by the FDA in June 2018, tofacitinib is an oral medication used to treat moderate to severe rheumatoid arthritis. It is a JAK inhibitor that reduces inflammation and joint damage.
  4. Bimekizumab (Bimekizumab): In 2018, UCB announced positive results from a phase 2 clinical trial of bimekizumab, an IL-17A and IL-17F inhibitor, for the treatment of psoriasis and psoriatic arthritis.
  5. Deucravacitinib (Sotyktu): In 2018, Eli Lilly announced positive results from a phase 2 clinical trial of deucravacitinib, an oral JAK inhibitor, for the treatment of moderate to severe plaque psoriasis.
  6. Fenebrutinib (Fenebrutinib): In 2018, Genentech announced positive results from a phase 2 clinical trial of fenebrutinib, an oral BTK inhibitor, for the treatment of rheumatoid arthritis.
  7. Guselkumab (Tremfya): In 2018, Janssen Biotech announced positive results from a phase 3 clinical trial of guselkumab, an IL-23 inhibitor, for the treatment of moderate to severe plaque psoriasis.
  8. Idecabtagene vicleucel (CAR-T cell therapy): In 2018, Novartis announced positive results from a phase 2 clinical trial of idecabtagene vicleucel, a CAR-T cell therapy, for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
  9. Sarilumab (Kevzara): In 2018, Sanofi announced positive results from a phase 3 clinical trial of sarilumab, an IL-6 receptor antagonist, for the treatment of moderate to severe rheumatoid arthritis.
  10. Tirzepatide (Mounjaro): In 2018, Eli Lilly announced positive results from a phase 2 clinical trial of tirzepatide, a GLP-1 receptor agonist, for the treatment of type 2 diabetes.

These are just a few examples of new anti-inflammatory drugs that were approved or made significant progress in 2018. There are many more in development, and the field is constantly evolving as researchers continue to explore new targets and mechanisms for treating inflammatory diseases.